PharmaJet and EVA Pharma Partner to Bring Needle-Free Polio Immunization to Egypt
PharmaJet®, a global leader in needle-free injection technology, has announced a strategic distribution agreement with EVA Pharma affiliate ATR to provide needle-free injection systems for Egypt’s routine polio immunization program.
The agreement, signed at the CPHI meeting in Frankfurt on October 30, includes provisions for distribution of PharmaJet’s Tropis® intradermal system, technology transfer, and localized manufacturing. The collaboration aims to expand access to needle-free delivery solutions in Egypt and across the region while strengthening Egypt’s domestic production capabilities for medical technology.
PharmaJet’s Tropis® system provides significant benefits — including reduced immunization costs, lower vaccine hesitancy, and increased coverage — making it an effective and child-friendly solution for large-scale vaccination efforts. The initiative aligns with Egypt’s “1000 Golden Days” campaign, which focuses on enhancing child and maternal health from conception through age two.
This latest agreement builds on a Memorandum of Understanding (MOU) signed in July 2025 between PharmaJet, Egypt’s Unified Procurement Agency (UPA), and EVA Pharma, outlining plans for incorporating Tropis technology into UPA’s vaccine portfolio.
Riad Armanious, CEO of EVA Pharma, said:
“This collaboration puts children first. We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children across Africa sustainably.”
Paul LaBarre, Senior Vice President of Business Development at PharmaJet, added:
“We are proud to collaborate with ATR and EVA Pharma to localize needle-free manufacturing and delivery. This partnership represents a strategic step forward for PharmaJet in the Middle East and North Africa, accelerating the integration of needle-free intradermal vaccine delivery into Egypt’s national immunization programs and beyond.”
The partnership reflects Egypt’s growing leadership in biopharmaceutical innovation, while supporting global efforts to eradicate polio and strengthen pandemic preparedness through sustainable, high-impact healthcare technology.
